D-0469-2023 Class II Terminated

Recalled by Teva Pharmaceuticals USA Inc — Parsippany, NJ

FDA drug recall D-0469-2023 was initiated by Teva Pharmaceuticals USA Inc on Feb 23, 2023 and is designated Class II. Reason for recall: Failed Impurities Specification: Out-of-specification (OOS) stability test result was obtained for unspecified impurity. The recall status is terminated (terminated Nov 28, 2023). Affected quantity: 715,632 bottles.

Recall details

Product Type
Drugs
Report Date
Mar 22, 2023
Initiation Date
Feb 23, 2023
Termination Date
Nov 28, 2023
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
715,632 bottles

Product description

Clear Eyes, Once Daily, Eye Allergy Itch Relief, olopatadine hydrochloride ophthalmic solution, USP, 0.2%, Antihistamine, 2.5 mL (0.085 fl oz) bottle, Sterile, Distributed by Medtech Products Inc. Tarrytown, NY 10591, A Prestige Consumer Healthcare company, Made in Israel, UPC 678112000708; NDC 67172-504-01.

Reason for recall

Failed Impurities Specification: Out-of-specification (OOS) stability test result was obtained for unspecified impurity.

Distribution pattern

Nationwide in the U.S.A.

Code information

Lot #114349, Exp. 05/2023; 117396, Exp. 09/2023; 120128, Exp. 11/2023; 114371, Exp. 06/2023; 123781, Exp. 02/2024.

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0469-2023
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0469-2023. Report a data issue: hello@regdatalab.com.